Lacosamide Tablet, Film Coated
Product Images NDC 60687-687

9 FDA label images from American Health Packaging · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Lacosamide (NDC 60687-687). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

100 mg Lacosamide Tablet Blister (100 mg Blister)

100 mg Lacosamide Tablet Blister (100 mg Blister)
Lacosamide 100 mg film-coated tablets label from American Health Packaging, displaying multiple identical printings. The label shows the product name, strength, dosage form, barcode, lot number, and expiry date placeholders, with the manufacturer location in Columbus, Ohio.*
FDA Label Image

100 mg Lacosamide Tablets Carton (100 mg Carton)

100 mg Lacosamide Tablets Carton (100 mg Carton)
Lacosamide 100 mg tablets, USP film-coated oral tablets. The label shows a bottle containing 60 tablets (6 strips of 10 tablets each). The product is prescription-only and distributed by American Health Packaging. Storage instructions and safety warnings are included on the label.*
FDA Label Image

200 mg Lacosamide Tablet Blister (200 mg Blister)

200 mg Lacosamide Tablet Blister (200 mg Blister)
Packaging label sheet displaying multiple instances of Lacosamide Tablets USP, 200 mg film-coated tablets. Each label includes the drug name, strength, barcode, expiry date placeholder, lot number placeholder, and the labeler American Health Packaging located in Columbus, Ohio.*
FDA Label Image

200 mg Lacosamide Tablets Carton (200 mg Carton)

200 mg Lacosamide Tablets Carton (200 mg Carton)
Lacosamide 200 mg film-coated tablets label showing a bottle with 60 tablets (6 blister packs of 10). The label indicates it is a USP oral prescription drug by American Health Packaging. Storage instructions, usage directions reference, and safety warnings appear on the label, alongside an NDC number 60687-698-57.*
FDA Label Image

50 mg Lacosamide Tablet Blister (50 mg Blister)

50 mg Lacosamide Tablet Blister (50 mg Blister)
Labeled sheet containing multiple individual labels for Lacosamide 50 mg film-coated tablets. Each label includes the product name Lacosamide Tablet USP 50 mg, barcode, lot number, expiration date, and the American Health Packaging labeler information based in Columbus, Ohio.*
FDA Label Image

50 mg Lacosamide Tablets Carton (50 mg Carton)

50 mg Lacosamide Tablets Carton (50 mg Carton)
Lacosamide 50 mg oral film-coated tablets label displaying 60 tablets per bottle (6 blister packs of 10). The label includes the NDC number 60687-676-57 and indicates the product is for prescription use only, distributed by American Health Packaging. Additional storage and safety information is present on the label.*
FDA Label Image

Figure 1 (Median Percent Reduction in Seizure Frequency per 28 days from Baseline to the Maintenance Phase by Dose)

Figure 1 (Median Percent Reduction in Seizure Frequency per 28 days from Baseline to the Maintenance Phase by Dose)
A bar chart comparing median percent seizure reduction from baseline across three studies for lacosamide at different dosages versus placebo. The chart shows seizure reduction percentages on the vertical axis and treatment groups along the horizontal axis with data for placebo and lacosamide at doses of 200 mg, 400 mg, and 600 mg per day in Study 2; 400 mg and 600 mg in Study 3; and 200 mg and 400 mg in Study 4. Statistically significant reductions compared to placebo are indicated with asterisks.*
FDA Label Image

Structural Formula (Structure)

Structural Formula (Structure)
Chemical structure of the active ingredient Lacosamide. The structure depicts its molecular framework with specific functional groups including an amide, an ether, and a benzene ring.*
FDA Label Image

Figure 2 (Proportion of Patients by Responder Rate for Lacosamide Oral Solution and Placebo Groups in Studies 2, 3, and 4)

Figure 2 (Proportion of Patients by Responder Rate for Lacosamide Oral Solution and Placebo Groups in Studies 2, 3, and 4)
A responder rate curve chart showing the percentage of patients versus responder rate (equal to or greater), comparing placebo and three dosage levels of Lacosamide (200 mg/day, 400 mg/day, 600 mg/day). The chart illustrates improvement and worsening response rates among patient groups with sample sizes indicated for each group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.